Heron Therapeutics, Inc. (HRTX) Dividend History

Company News

• Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

  Heron Therapeutics, a commercial-stage biotechnology company, will host a conference call on November 12, 2024, to report its third quarter 2024 financial results and discuss recent business highlights.

  Benzinga
• Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR

  The global chemotherapy-induced nausea and vomiting treatment market is expected to grow at a CAGR of 6.4% and reach a valuation of US$ 12,688.0 million by 2034, driven by the increasing incidence of cancer and the need for effective management of CINV.

  GlobeNewswire Inc.

  Featured Companies: ABBV BHC MRK PFE
• Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

  Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.

  Zacks Investment Research

  Featured Companies: BVS MRK
• FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

  Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.

  Zacks Investment Research

  Featured Companies: ARQT CGEN RCKT
• FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma

  Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.

  Zacks Investment Research

  Featured Companies: ABBV ARQT